Helping Make Early Prostate Cancer Detection a Reality

While national screening programmes exist in the UK for numerous different cancers, there is currently no targeted or population-wide screening programme for prostate cancer.

Yesterday, Prostate Cancer Research (PCR) hosted an event at the House of Commons to launch their new report, “Prostate Cancer Screening: The Impact on the NHS.”

The report outlines how a targeted national screening programme for high-risk groups could be implemented, an important step toward improving early detection and reducing mortality from prostate cancer across the UK. Find out the report’s key findings here.

Cambridge Clinical Laboratories (CCL), acquired by Source BioScience UK Ltd, is proud to support this vision by enabling earlier and more effective diagnosis of prostate cancer through validated biomarker tests such as Proclarix and Stockholm3. Both tests are highlighted in the PCR report for their clinical value in improving risk stratification, enhancing diagnostic specificity, and reducing unnecessary MRI scans and biopsies, supporting the evolution of prostate cancer screening toward greater precision, efficiency, and patient benefit.

For more information on these tests, please get in touch with us here.